Form 4: Aptevo Therapeutics CEO Reports Stock Transaction
Insider Transaction (Form 4)
Jeffrey G. Lamothe, President and CEO and a Director of Aptevo Therapeutics Inc., reported multiple transactions in common stock on August 6, 2026.
Summary
- Option exercise/conversion: acquired 961 Common Stock on August 6, 2026; holds 961 after (Direct).
- Option exercise/conversion: disposed of 961 Restricted Stock Unit on August 6, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jeffrey G. Lamothe — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-06 | Option exercise/conversion | Common Stock | 961 | — | — | 961 |
| 2026-08-06 | Option exercise/conversion | Restricted Stock Unit | 961 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-06 | Option exercise/conversion (961 shares) |
| 2026-08-06 | Option exercise/conversion (961 shares) |
Keywords
insider transaction, Form 4, APVO, Aptevo Therapeutics Inc., neutral, Jeffrey G. Lamothe
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.